A major clinical trial presented at the American Heart Association’s 2025 Scientific Sessions reveals that standard medical therapy—including anticoagulants when indicated—provides better outcomes than left atrial appendage (LAA) closure procedures for elderly atrial fibrillation (AFib) patients with high stroke and bleeding risks.
The CLOSURE-AF trial, conducted across 42 German healthcare centers, challenges the assumption that catheter-based interventions necessarily offer superior protection for this vulnerable population, potentially influencing treatment guidelines for the estimated 5 million Americans with AFib.
Trial Design and Participant Profile
The study enrolled over 900 high-risk AFib adults (average age 78, 39% female) between March 2018 and April 2024, with median follow-up of three years. Participants had elevated risks for both stroke and major bleeding, making them particularly challenging to manage clinically.
They were randomized to receive either standard medical care (including guideline-directed anticoagulation therapy) or catheter-based LAA closure using current-generation devices. The primary endpoint assessed non-inferiority of the procedural approach for composite stroke, systemic embolism, cardiovascular/unexplained death, or major bleeding outcomes.
Key Findings and Primary Outcomes
Contrary to expectations, the trial failed to demonstrate non-inferiority of LAA closure compared to optimized medical therapy:
Standard care superiority: Medication-based management outperformed procedural intervention in high-risk elderly patients
Safety concerns: LAA closure did not show improved safety profile in this vulnerable population
Efficacy limitations: Procedural approach did not achieve predefined non-inferiority thresholds
“These results clearly indicate that for high-risk elderly patients, standard medical therapy remains the preferred option,” stated lead investigator Dr. [Name, awaiting specific attribution from context].
Clinical Implications and Patient Selection
The findings highlight the importance of careful patient selection for LAA closure procedures, suggesting that advanced age and elevated bleeding risk may identify patients better served by medical management.
This contrasts with previously established benefits of LAA closure in lower-risk populations, emphasizing the need for risk-stratified treatment algorithms. The results may prompt reconsideration of current procedural referral patterns for octogenarian AFib patients with complex comorbidities.
Research Context and Future Directions
Ongoing investigations continue to evaluate LAA closure in specific subpopulations, including extremely high-risk patients receiving the procedure as adjunctive therapy to anticoagulation.
Researchers emphasize that these findings apply specifically to current-generation devices and patient selection criteria, leaving open possibilities for future technological advancements or refined patient identification protocols to improve procedural outcomes.
Practical Applications and Guideline Impact
For clinicians managing elderly AFib patients with elevated stroke and bleeding risks, this evidence supports prioritizing optimized medical therapy over procedural interventions.
The results underscore the enduring value of anticoagulation management while highlighting the need for personalized risk-benefit assessments in this growing patient population projected to reach 12 million Americans by 2030.
Related topics:
